Zenas BioPharma Reports Q2 2026 Results; Appoints New Director

What Happened

• Zenas BioPharma, Inc. filed a Current Report on Form 8-K on August 13, 2026 to announce its financial results for the quarter ended June 30, 2026; the related press release was furnished as Exhibit 99.1 to the filing.
• The company’s board appointed Christy J. Oliger as a Class II director, effective September 1, 2026; she will hold office until the annual meeting of stockholders in 2029 (or until her successor is elected).

Key Details

• Filing date: August 13, 2026; quarter covered: ended June 30, 2026 (Q2 2026).
• Director appointment effective: September 1, 2026; term through 2029 annual meeting.
• Initial compensation for Ms. Oliger: a non‑qualified stock option to purchase 37,000 shares, plus cash board/committee fees per the company’s Non‑Employee Director Compensation Policy (amended January 1, 2026).
• Board actions: increased authorized board size by one; Ms. Oliger will serve on the Nominating & Corporate Governance Committee and the Science & Technology Committee and is deemed independent under Nasdaq standards. She has entered into the company’s standard indemnification agreement and no related‑party transactions were reported.

Why It Matters

• The 8‑K signals the release of the company’s quarterly financial results (investors should read the press release for revenue, earnings, cash position and other metrics that could affect the stock).
• The addition of an independent director increases board capacity and may affect governance and committee composition; the option grant (37,000 shares) is a potential future dilution if exercised.
• No related‑party transactions were disclosed in connection with the appointment, and standard indemnification is in place — items investors often review when assessing governance risk.